曲安奈德鼻喷雾剂治疗变应性鼻炎疗效观察

目的：观察曲安奈德鼻喷雾剂治疗变应性鼻炎的临床疗效。方法：回顾性分析我院2011年11月～2013年12月收治的96例变应性鼻炎患者的临床资料,随机分为观察组和对照组,对照组给予氯雷他定片治疗,观察组在对照组的基础上给予曲安奈德鼻喷雾剂治疗,观察两组的疗效。结果：观察组总有效率（95.83%）高于对照组（79.17%）,差异有统计学意义（P<0.05）。结论：曲安奈德鼻喷雾剂治疗变应性鼻炎疗效显著,安全性好,值得临床推广。     

曲安奈德治疗变应性鼻炎68例

目的观察曲安奈德治疗变应性鼻炎的临床疗效及安全性。方法选择2008年6月至2011年6月收治的变应性鼻炎患者136例,随机分成两组,每组68例。对照组给予口服盐酸西替利嗪片治疗,治疗组给予曲安奈德喷雾剂治疗,两周为1个疗程,连续治疗两个疗程。比较两组患者临床总有效率及不良反应发生情况。结果对照组临床总有效率为82.35%,治疗组临床总有效率为94.12%,两组比较差异有统计学意义(P<0.05)。对照组不良反应发生率为19.12%,治疗组不良反应发生率为8.82%,两组比较差异有统计学意义(P<0.05)。结论曲安奈德治疗变应性鼻炎,疗效显著且不良反应少,值得临床推广。     

曲安奈德鼻喷雾剂治疗慢性单纯性鼻炎的疗效观察

目的探讨曲安奈德鼻喷雾剂治疗慢性单纯性鼻炎的临床疗效。方法 108例慢性单纯性鼻炎的患者,随机分为对照组和治疗组,每组54例。对照组采用常规的治疗方法,治疗组采用曲安奈德鼻喷雾剂进行治疗,治疗3个月,观察两组患者的临床效果。结果治疗组的总有效率为92.59%,明显高于对照组的87.04%,两组相比差异有统计学意义（P〈0.05）;两组患者的临床症状与治疗前相比均有明显的改善（P〈0.05）,鼻塞、喷嚏、鼻痒,两组比较差异无统计学意义（P〉0.05）;在患者的流涕以及鼻黏膜肿胀方面,治疗组的改善情况要优于对照组,两组相比差异有统计学意义（P〈0.05）;观察组的不良反应少于对照组。结论曲安奈德鼻喷雾剂在治疗慢性单纯性鼻炎方面,疗效确切,治疗简单,值得在临床上推广使用。     

曲安奈德鼻喷雾剂治疗过敏性鼻炎的临床研究

目的评价曲安奈德鼻喷雾剂治疗过敏性鼻炎的临床疗效及安全性,方法以丙酸倍氯米松鼻喷雾剂(商品名伯克纳)为对照药,采用开放性、随机对照、多中心临床试验的方法治疗过敏性鼻炎160例.剂量用法曲安奈德鼻喷雾剂,鼻腔喷入,每次每鼻孔2揿,每日1次,每揿55μg;丙酸倍氯米松鼻喷雾剂,鼻腔喷入,每次每鼻孔2揿,每日2次,每揿50μg.疗程均为2周.结果曲安奈德鼻喷雾剂与丙酸倍氯米松鼻喷雾剂临床疗效评价例数分别为100例和60例,两药临床有效率分别为8 8%和90%,药物不良反应发生率分别为13%和10%.以上结果经统计学处理均无显著差异(P＞0.05).结论曲安奈德鼻喷雾剂治疗过敏性鼻炎安全有效.     

曲安奈德局部应用治疗变应性鼻炎的疗效观察

目的观察曲安奈德下鼻甲黏膜下注射治疗变应性鼻炎的临床疗效。方法治疗组35例变应性鼻炎患者给予曲安奈德注射液双侧下鼻甲黏膜下注射,20mg/次,1次/周,5周为1个疗程;对照组35例给予丙酸倍氯米松鼻喷雾剂双侧鼻腔喷雾,400mg/次,2次/d,5周为1个疗程。结果治疗组总有效率为94.2%,对照组总有效率为68.5%,两组比较差异有统计学意义(P<0.05)。结论曲安奈德治疗变应性鼻炎临床疗效确切,能有效降低患者血清白细胞介素水平,发挥抗炎抗过敏作用,且安全有效。     

曲安奈德局部注射治疗变应性鼻炎的疗效观察

目的探讨曲安奈德局部注射治疗变应性鼻炎的疗效。方法将我院收治的应性鼻炎患者共100例分成实验组和对照组,各50例,实验组采用曲安奈德局部注射治疗,对照组口服盐酸西替利嗪片治疗,观察两组患者疗效、不良反应以及随访中复发情况。结果实验组总有效率为94.0%,对照组为78.8%,实验组总有效率明显高于对照组(P<0.05);实验组治疗后TSS积分明显优于对照组(P<0.05);不良反应发生率和复发率明显低于对照组(P<0.05)。结论曲安奈德局部注射治疗变应性鼻炎疗效确切,不良反应少,复发率低,是一种安全可靠的治疗方式。     

曲安奈德治疗过敏性鼻炎

目的：观察曲安奈德对过敏性鼻炎的疗效和不良反应。方法：典型的过敏性鼻炎５０例，男性１９例，女性３１例，年龄３８±ｓ１０ａ，用曲安奈德５０～１００ｍｇ，ｉｍ，隔日１次，共２次。结果：所有病人症状迅速缓解，但会复发，平均复发间隔时间为９．７±１．３ｍｏ；不良反应有女性病人皆出现不同程度的月经改变。结论：曲安奈德治疗过敏性鼻炎有效，但皆有复发，且有月经过多。     

曲安奈德鼻喷雾剂治疗儿童过敏性鼻炎的临床疗效观察

目的观察曲安奈德鼻喷雾剂治疗儿童过敏性鼻炎的临床疗效。方法随机选择门诊就诊的儿童过敏性鼻炎患者76例,每天应用曲安奈德鼻喷雾剂一次,每次各鼻孔一喷(110μg/d),连续使用,最长不超过30d。结果曲安奈德鼻喷雾剂治疗儿童过敏性鼻炎10d有总效率达78.95%,20d有总效率达88.16%,30d总有效率达93.42%;与治疗前后比较,治疗后10d、20d、30d各项症状改善情况有明显变化,统计学指标P<0.01。结论曲安奈德鼻喷雾剂对治疗儿童过敏性鼻炎方面有显著疗效,使用方便,不良反应轻,适于儿科临床应用。     

曲安奈德鼻喷剂治疗变应性鼻炎临床观察

目的评价曲安奈德鼻喷剂治疗变应性鼻炎（allergicrhinitis,AR）的临床疗效和药物安全性。方法132例AR患者采用随机、对照方法,治疗组67例,用曲安奈德鼻喷剂喷鼻,1次/d,每次各鼻孔2揿（共220μg/d）;对照组65例,用布地奈德鼻喷剂喷鼻,1次/d,每次各鼻孔2揿（共256μg/d）;疗程均为4w。分别分析、评估药物的疗效和安全性。结果治疗一疗程后,大部分患者临床表现均有明显改善;治疗组总有效率为92.5%,对照组为93.8%;治疗组不良反应发生率为10.4%,对照组为9.2%。两组治疗前后临床表现比较有统计学意义（P〈0.05）,两组总有效率比较差异无统计学意义（P〉0.05）,两组不良反应比较差异无统计学意义（P〉0.05）。结论曲安奈德鼻喷剂局部应用见效快,效果好,能有效缓解AR患者鼻部症状,安全性好。     

FDA批准曲安奈德鼻用喷雾剂用于2～5岁儿童变应性鼻炎

2008年9月23日，Sanofi-aventis（赛诺菲-安万特）制药公司宣布，FDA批准Nasacort AQ Nasal Spray（triamcinolone acetonide，曲安奈德鼻用喷雾剂）用于2～5岁儿童治疗季节性及常年性变应性鼻炎。Nasacort AQ Nasal Spray是美国FDA批准的首个以氟烷（HFA）替代氟氯化碳（CFCs）的鼻用糖皮质激素干粉气雾剂，起效快速，12～16h即可缓解症状，     

敏停喷鼻剂对TDI致豚鼠过敏性鼻炎模型的影响

目的研究敏停喷鼻剂对豚鼠过敏性鼻炎模型的影响。方法用TDI致豚鼠过敏性鼻炎造模型，观察敏停喷鼻剂对过敏性鼻炎模型的鼻部过敏症状以及鼻黏膜病理组织形态学的影响。结果敏停喷鼻剂能明显减轻豚鼠过敏性鼻炎模型鼻部过敏症状以及鼻黏膜上皮炎细胞的浸润。结论敏停喷鼻剂对过敏性鼻炎可能具有较好的疗效。     

曲安缩松治疗过敏性鼻炎91例的临床疗效

目的：观察小剂量曲安缩松加入呋麻滴鼻液中，在鼻腔内局部应用，对过敏性鼻炎的治疗的临床疗效，方法：帮央安缩松２ｍｇ加入呋麻滴鼻液８ｍｌ中，使其充分混合；对９１例过敏性鼻炎患者局部滴鼻ｔｉｄ－ｑｉｄ；２－３滴／次。结果；小剂量曲安缩松加入呋麻滴鼻液中滴鼻治疗过敏性鼻炎，有效率９３．４０％，显效率５９．３４％。结论；用小剂量曲安缩松局部应用对过敏性鼻炎有明显抗过敏作用，并见效快，应用方便，无不良反应，但     

Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis

AIMS: To evaluate the systemic bioactivity of triamcinolone acetonide (TA) 220 micro g or mometasone furoate (MF) 200 micro g over 3 weeks in perennial allergic rhinitis. METHODS: Twenty-seven patients received TA 220 micro g or MF 200 micro g once daily for 3 weeks with a 2 week placebo washout period prior to each randomized treatment. Measurements were made at baseline after each washout and after each randomized treatment, comprising overnight 10-h urinary cortisol corrected for creatinine (OUCC), 08.00 h plasma cortisol and 08.00 h serum osteocalcin. RESULTS: There were no significant differences between baseline values prior to TA or MF, and for any outcome measures comparing randomized treatments to respective baseline values or comparing TA with MF. For OUCC compared with baseline, the geometric mean fold suppression (95% CI) was 1.02 (0.78, 1.33) for TA (2% decrease), 1.07 (0.80, 1.42) for MF (7% decrease), and 1.05 (0.79, 1.39) for TA vs MF (5% decrease). CONCLUSIONS: Standard doses of TA or MF over 3 weeks showed no differences in systemic bioactivity markers compared with respective baseline values after placebo washout, and there were no differences between TA vs MF.     

甘辛鼻腔用喷雾剂对豚鼠超敏鼻炎的治疗作用

目的:观察甘辛鼻腔用喷雾剂对豚鼠超敏性鼻炎的疗效.方法:采用甲苯-2-4-二异氰酸酯(TDI)诱导豚鼠超敏性鼻炎反应模型,实验一选择30只模型动物随机分为2组,观察给药组和空白对照组豚鼠鼻黏膜组织的病理变化.实验二选用健康豚鼠50只,随机分为5组,其中1个组为健康受试组,另外4组通过TDI诱导造成豚鼠超敏性鼻炎反应模型.以迪通鼻炎水(市售)为阳性药物,观察健康受试组、给药组(高、低剂量组,每次每侧用10,5μL,bid)、阳性对照组、空白对照组的豚鼠鼻黏膜组织病理变化.结果:实验一中给药组与空白组相比豚鼠鼻黏膜上皮下嗜酸性粒细胞、淋巴细胞、浆细胞浸润显著减少,腺体增生也显著减少(P<0.01).实验二中高、低2个剂量组均使豚鼠鼻黏膜上皮下嗜酸性粒细胞、淋巴细胞、浆细胞和嗜中性粒细胞显著减少,腺体增生和分泌亢进得到有效的抑制,疗效与阳性对照组相似.结论:甘辛鼻腔用喷雾剂可有效抑制超敏反应过程,保护鼻黏膜.     

Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis

STUDY OBJECTIVE: To systematically review the efficacy of azelastine nasal spray for the treatment of allergic rhinitis. DESIGN: Meta-analysis of published randomized controlled trials reported in English. DATA SOURCE: Published literature from the PubMed-MEDLINE database. PATIENTS: Patients aged at least 12 (United States) or 16 years (Europe) with allergic rhinitis or nonallergic vasomotor rhinitis. MEASUREMENTS AND MAIN RESULTS: A global assessment of efficacy was used to estimate the number needed to treat for azelastine nasal spray compared with placebo or active comparators. The total symptom score was used to compare the effect size between azelastine and placebo. In five comparisons of azelastine and placebo, azelastine was most efficacious, with a summary number needed to treat of 5.0 (95% confidence interval [CI] 3.3-10.0). In reviewing 11 studies of azelastine versus active comparators, we found no significant difference between azelastine and active comparators (number needed to treat 66.7, 95% CI 14.3 to infinity to 25). Azelastine was more efficacious than placebo in terms of total symptom score (effect size of 0.36, 95% CI 0.26-0.46). CONCLUSION: Azelastine nasal spray was more efficacious than placebo in the treatment of allergic rhinitis. No significant differences were observed between azelastine and active comparators for the treatment of allergic rhinitis; however, when azelastine was compared with oral antihistamines as monotherapy, the trend favored azelastine. Because azelastine appears to be as efficacious as oral antihistamines, the choice of treatment for seasonal allergic rhinitis should depend on the patient's preference regarding the route of administration, adverse effects, and the cost of the drug.     

曲安奈德鼻喷雾剂治疗过敏性皮炎疗效观察

目的观察曲安奈德鼻喷雾剂治疗过敏性皮炎的临床疗效和安全性。方法 92例患者分为观察组和对照组各46例。观察组给予曲安奈德鼻喷雾剂治疗;对照组给予丁酸氢化可的松乳膏治疗。观察2组病情积分、起效时间、临床疗效及不良反应。结果 治疗中脱落8例,其中观察组3例,对照组5例。2组治疗后病情积分、起效时间及临床疗效比较差异均无统计学意义(P>0.05)。2组治疗后病情积分均低于治疗前,差异有统计学意义(P<0.01)。观察组发生不良反应4例占9.30%,对照组发生4例占9.76%。结论曲安奈德鼻喷雾剂治疗过敏性皮炎安全、有效,值得临床推广使用。     

布地奈德对变应性鼻炎豚鼠鼻粘膜嗜酸性粒细胞及组胺的影响

目的：制备变应性鼻炎动物模型,评价布地奈德对变应性鼻炎嗜酸性粒细胞和组胺的影响.方法：将豚鼠随机分成自然对照组、变应性鼻炎组和布地奈德治疗组,采用甲苯-2,4-二异氰酸酯对豚鼠鼻腔局部致敏激发制备变应性鼻炎模型,通过观察动物临床症状、鼻粘膜病理切片和鼻粘膜组织中组胺含量等指标来评价药物的药效.结果：变应性鼻炎组鼻粘膜组织中嗜酸细胞浸润和组胺含量均显著高于自然对照组（P＜0.01或P＜0.05）;经治疗后,动物的嗜酸细胞浸润和组织中组胺含量均明显地降低（P＜0.01）.在临床症状指标上,变应性鼻炎组和药物治疗组评分均明显高于自然对照组（P＜0.01）,但变应性鼻炎组和药物治疗组间无显著差异（P＞0.05）.结论：布地奈德能有效地降低变应性鼻炎豚鼠鼻粘膜组织中嗜酸细胞浸润和组胺的含量,但未能改善动物的鼻部临床症状,这可能与造模的方法有关.     

右布地奈德鼻喷雾剂治疗过敏性鼻炎的临床对照研究

目的:对右布地奈德鼻喷雾剂治疗过敏性鼻炎的有效性和安全性进行评价,并与布地奈德鼻喷雾剂比较。方法:采用多中心、随机、开放、平行对照的临床试验,符合入选标准的过敏性鼻炎患者共222例,分成2组:右布地奈德组(试验组)110例,布地奈德组(对照组)112例。试验组给予右布地奈德鼻喷雾剂,25μg/喷,每次每个鼻孔2喷,早晚各1次;对照组给予布地奈德鼻喷雾剂,64μg/喷,每次每个鼻孔1喷,早晚各1次。2组均连续用药14d。疗效评价以症状积分下降指数作为主要指标,生活质量改善程度作为次要指标。结果:试验组和治疗组相比,症状积分下降指数、生活质量改善程度、不良反应发生率均相似,即0.78±0.24,0.76±0.23;96.4%,94.6%;以及13.6%,14.3%。结论:右布地奈德鼻喷雾剂治疗过敏性鼻炎与布地奈德鼻喷雾剂同样安全有效。     

Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis

Summary

The efficacy and safety of the nasally administered histamine H₁ receptor blocking drug azelastine was investigated in a randomized comparative trial with ebastine. Patients were treated for 14 days and efficacy was assessed by the physician using a rating scale measuring 10 nasal and ocular symptoms of seasonal rhinitis (0 = absent, 1 = mild, 2 = moderate, 3 = severe). Tolerability was measured on the basis of reported adverse events. Data from a total of 59 patients were included in the efficacy analysis. Both treatment groups had dramatic reductions in the physician's total symptom score following treatment. Mean scores in the azelastine group decreased from 12.4 pretreatment to 5.6, while the mean ebastine scores decreased from 13.6 to 6.6. There was no significant difference between the two groups (p= 0.86). Changes in individual rhinitis symptoms showed no differences between the two groups. The majority of patients in both treatment groups reported an initial relief of symptoms within 1?h of dosing. For seven patients treated with azelastine, the initial effect was already seen after 10?min (ebastine: two patients). Eight adverse events were reported in each treatment group; all were mild except one report of sedation in an ebastine patient, which was of moderate severity. Three patients reported somnolence during treatment with ebastine. A bitter taste was mentioned by four patients in the azelastine group, but neither somnolence nor sedation was reported with azelastine. In conclusion, the results of the study suggest that both azelastine and ebastine are effective treatments of the symptoms of seasonal allergic rhinitis. Both drugs were well tolerated.     

Dose-ranging study of fluticasone furoate nasal spray for Japanese patients with perennial allergic rhinitis

ABSTRACT

Background: This study was designed to evaluate the efficacy and safety of fluticasone furoate nasal spray (FFNS), a novel enhanced-affinity intranasal corticosteroid, in Japanese patients with perennial allergic rhinitis (PAR), and to determine the optimal dose.

Methods: In this phase II, multicenter, double-blind, randomized, placebo-controlled, parallel-group, dose-ranging study, 240 patients (aged ≥ 16 years) received once-daily (od) treatment for 2 weeks with either FFNS 110 μg (n = 80), 220 μg (n = 81) or placebo (n = 79). Patients evaluated 3 nasal symptoms using a 4-point scale. Efficacy was assessed as the mean change from baseline in total nasal symptom score (TNSS).

Results: Treatment with FFNS resulted in a significantly greater decrease over the treatment period in the mean 3TNSS (sneezing, rhinorrhea, and nasal congestion; p < 0.001 each dose vs. placebo), compared with placebo. More patients receiving FFNS had a markedly or moderately improved impression of treatment than placebo recipients (48% and 49% for FFNS 110 μg and 220 μg, respectively, vs. 18% for placebo; p < 0.001). Nasal rhinoscopy findings revealed significant improvements in mucosal swelling of the inferior turbinate (110 μg: p = 0.004; 220 μg: p = 0.011) and amount of watery rhinorrhea (110 μg: p = 0.003; 220 μg: p < 0.001), compared with placebo. Both doses of FFNS were well tolerated.

Conclusions: Both FFNS 110 µg and 220 µg od were effective in alleviating nasal symptoms in Japanese patients with PAR over the 2-week duration of this study. FFNS 110 µg od was selected as the optimal dose for further evaluation in phase III clinical trials.